Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.
Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas
Dr. Blay on Treatment Considerations in Soft Tissue Sarcomas
Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.
Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomas
Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.
Dr. Martin-Broto on the Current First-Line Treatment of Soft Tissue Sarcomas
Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.
Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.
Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.
MDM2 Pulls Novel Treatments Into Focus for Underserved Liposarcoma Population
Amplification of murine double minute 2 represents a promising target to access the so-called cellular gatekeeper p53 protein in human cancers.
Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma
Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.
Dr. Blay on the Current Treatment Challenges in Soft Tissue Sarcomas
Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.
Dr. LoRusso on the Efficacy of BI 907828 in Solid Tumors
Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.
Dr. Blay on the Exploration of BI 907828 in Patients With Sarcoma
Jean-Yves Blay, MD, discusses the exploration of BI 907828 in patients with sarcoma.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.